Altimmune (ALT) said Thursday that its phase 2b trial of its product candidate pemvidutide has met its primary endpoint with "statistically significant" metabolic dysfunction-associated steatohepatitis, or MASH, resolution.
The company said pemvidutide showed significant MASH effects and weight loss at 24 weeks.
An intent-to-treat analysis showed that MASH resolution without worsening of fibrosis was achieved in 59.1% and 52.1% of participants treated with 1.2 mg and 1.8 mg, respectively, compared with 19.1% of participants treated with placebo, Altimmune said.
An additional intent-to-treat analysis showed that 31.8% and 34.5% of participants treated with pemvidutide 1.2 mg and 1.8 mg improved their fibrosis without worsening their MASH, compared with 25.9% in the placebo group, with "differences not significant," the company said.
The average weight loss in patients treated with pemvidutide at 24 weeks was 5% and 6.2% for the 1.2 mg and 1.8 mg doses, respectively, compared with 1% in placebo, Altimmune said.
Shares of Altimmune were down 63% in recent Thursday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.